Sunnyvale, CA, September 19, 2003--Picoliter Inc. announced today it has been
awarded four additional U.S. patents, which extend its intellectual property to
include the use of focused acoustic energy (ultrasound) to create miniaturized
assay arrays, to generate particles for pharmaceutical and other applications,
and to prepare samples for mass spectrometers.
Picoliter believes the inventions described in these patents will enable
researchers to dramatically improve liquid handling in a broad set of life
science applications.
The economics of industrialized biology continue to fuel the desire for
reduction in assay volumes as a way to decrease the cost per data point through
more efficient use of expensive reagents and improved automation. However, a major barrier to
decreasing cost has been the lack of reliable instrumentation for small volume
transfers. The Picoliter®
liquid handling technology, covered in the company’s two previously issued and
four new patents, provides a unique solution to the small volume transfer
problem. This technology has been demonstrated to reliably transfer droplets as
small as 0.1 picoliter (a picoliter
is a millionth of a millionth of a liter) with no contact between the device
and the solution being transferred.
“Our new patents illustrate the breadth and power of acoustic droplet ejection technology and are expected to form the basis of future products in the areas of drug discovery, genomics and proteomics. Even as we are preparing for the introduction of our first product, the Echo 550, which solves the problem of reliably delivering low nanoliter volumes in high throughput screening, the team continues to develop the pipeline of products in additional areas of life science,” said Elaine J. Heron, Ph.D., Chief Executive Officer of Picoliter Inc.
Picoliter Inc. is a privately held
company located in Sunnyvale, California.
The Picoliter® liquid handling technology has broad
applications in the life science including dispensing equipment, assay systems,
sample preparation, particle manufacturing, microarrays,
and living cell transfer devices. The
company’s first product, the Echo 550, will be a system for precisely
transferring low nanoliter volumes of potential drug
compounds into assay plates. For more
information, visit the company’s website, www.picoliterinc.com.
Contact information:
Elaine J. Heron, Ph.D.
Chief Executive Officer
Picoliter Inc.
1190 Borregas Avenue
Sunnyvale, CA 94089
(408) 747-2000 x 108
(408) 747-2009 (FAX)
www.picoliterinc.com